Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets.
Prognosis of PTCL is generally poor when treated with conventional chemotherapy regimens used in B-cell aggressive lymphomas. Recent advances in genomic and molecular profiling of PTCL have allowed to further insight this heterogeneous group of neoplasias and their main prognostic factors. This review will try to summarize the main clinical problems related to standard frontline and salvage therapy, including the use of conventional chemotherapy and high-dose, dose-dense and immunotherapeutic strategies, as well as new approaches based on biological knowledge and the use of new drugs or immunotherapy.
Rodríguez
J
J
Service of Oncology, General University Hospital Gregorio Marañon, Madrid, Spain. joseguez89@hotmail.com
Gutiérrez
A
A
Martínez-Delgado
B
B
Perez-Manga
G
G
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000037:antagonists & inhibitors* / Q000235:genetics; D002869:Chromosome Aberrations; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends*; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D023281:Genomics / Q000379:methods; D006801:Humans; D007167:Immunotherapy / Q000379:methods / Q000639:trends; D016411:Lymphoma, T-Cell, Peripheral / Q000175:diagnosis / Q000235:genetics / Q000473:pathology* / Q000628:therapy*; D009361:Neoplasm Invasiveness; D033581:Stem Cell Transplantation / Q000379:methods
D014408:Biomarkers, Tumor